Wegovy maker Novo Nordisk's board slims down as directors quit
Summary
Novo Nordisk, the maker of popular weight-loss and diabetes drugs, is seeing major changes in its board members with seven directors, including the chairman, deciding not to return. This follows a period of significant changes, including a new CEO and job cuts due to increased competition and profit concerns. The Novo Nordisk Foundation, owning a major stake, has influenced these shifts.Key Facts
- Novo Nordisk makes weight-loss drug Wegovy and diabetes drug Ozempic.
- Seven board members, including chairman Helge Lund, will leave the board.
- The departures coincide with the company's reduced profit growth projections.
- The Novo Nordisk Foundation owns 28.1% of the shares and controls voting.
- Competition from companies like Eli Lilly has affected Novo Nordisk's stock value.
- The Foundation previously replaced the former CEO in May.
- Lars Rebien Sorensen is proposed as the new chairman.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.